IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT01041222
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Methodist Neurological Institute, Houston, Texas, United States
Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00836225
- Locations
- 🇳🇱
Center for Human Drug Research, Leiden, Netherlands
Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2010-07-29
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00734240
- Locations
- 🇨🇦
Anapharm, Montreal, Quebec, Canada
Safety Study of ISIS 325568 in Healthy Volunteers
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2008-08-19
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00519727
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2009-08-28
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT00455598
- Locations
- 🇷🇴
Oradea Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases, Oradea, Romania
🇷🇺Limited Liability Company "Clinic of New Medical Technologies", Moscow, Russian Federation
🇷🇴Private Practice "Morosanu V. Magdalena", Galati, Romania
Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2007-10-17
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00365781
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2008-02-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT00330330
- Locations
- 🇷🇺
Close Corporation "MEDSI", Moscow, Russian Federation
🇵🇱NZOZ Specjalistyczny Osrodek Internistyczno Diabetologiczny, Bialystok, Poland
🇵🇱Prywatna Praktyka Lekarska, Radom, Poland
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT00330200
- Locations
- 🇺🇸
Yale - New Haven Hospital, New Haven, Connecticut, United States
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT00327626
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Western Galilee Medical Center - Nahariya, Nahariya, Israel
🇮🇱Soroka Medical Center, BeEr-Sheva, Israel
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-02-04
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT00017407
- Locations
- 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸ISIS Pharmaceuticals, Inc., Carlsbad, California, United States